Robotic Biopsy Devices Market Size, Share, Growth, and Industry Analysis, By Type (Brain Biopsy,Lung Biopsy,Prostate biopsy), By Application (Hospitals,Ambulatory Surgical Centers,Academic & Research Institutes), Regional Insights and Forecast to 2035

Robotic Biopsy Devices Market Overview

The global Robotic Biopsy Devices Market is forecast to expand from USD 433.41 million in 2026 to USD 486.11 million in 2027, and is expected to reach USD 1217.42 million by 2035, growing at a CAGR of 12.16% over the forecast period.

The global Robotic Biopsy Devices Market Market reached a valuation of about USD 424.3 million in 2023 and registered systems & instruments capturing over 55.9% of revenue share in that year. In 2023 the lung biopsy application segment held approximately 44.1% share of the market. According to industry data, around 65% of tertiary care hospitals now employ robotic-assisted biopsy equipment for lung, prostate and brain procedures. Over 62% of product enhancements in 2023 stem from collaborations between robotics and imaging companies.

In the United States the Robotic Biopsy Devices Market Market accounted for nearly 87.4% of the North America regional segment in 2023. U.S. hospital adoption of robotic biopsy systems reached approximately 70% of large cancer-centre units in 2023. Lung biopsy applications captured around 44% of U.S. robotic biopsy usage in 2023. Prostate biopsy robotic systems achieved nearly 33% share of U.S. application demand in 2023. The U.S. remains the most advanced national market in the Robotic Biopsy Devices Market Market, offering sizeable B2B opportunities for system manufacturers, service providers and imaging-guided device suppliers.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Increased incidence of cancer and minimally invasive diagnostics drive roughly 52% of equipment adoption.
• Major Market Restraint: High device cost and reimbursement limitations restrict approximately 38% of procedure-site expansion.
• Emerging Trends: Autonomous needle-guidance and AI-navigation systems represent about 18% share of new product introductions.
• Regional Leadership: North America holds around 57.8% share of the global Robotic Biopsy Devices Market Market in 2023.
• Competitive Landscape: Top five companies command nearly 62% of global market share in system shipments.
• Market Segmentation: Lung biopsy represents about 44% of application volume globally; brain biopsy around 28%, prostate biopsy near 33%.
• Recent Development: The instrument & accessories segment achieved 55.9% share of revenue in 2023.

Robotic Biopsy Devices Market Latest Trends

In the Robotic Biopsy Devices Market Market, major trends include the rapid shift toward imaging-guided automation, growing use of lung biopsy applications, and increasing penetration of robotic systems in outpatient settings. In 2023 the lung biopsy application held about 44.1% share globally, and tertiary hospitals reporting use of robotic assisted biopsy reached around 65%. Instruments & accessories comprised about 55.9% of revenue share in 2023. Autonomous systems, AI navigation enhancements and multi-organ compatibility were introduced in about 18% of new devices in 2023. In the U.S., large cancer centres (>200 beds) equipped approximately 70% of units with robotic biopsy systems. For B2B equipment manufacturers and service providers in the Robotic Biopsy Devices Market Market, these developments mean focus is shifting toward after-sales service, device upgrades and multi-specialty compatibility. The Robotic Biopsy Devices Market Market Analysis offers insight into how precision robotics, imaging integration and minimally invasive diagnostics are converging for next-generation biopsy platforms.

Robotic Biopsy Devices Market Dynamics

DRIVER

"Rising incidence of targeted cancers and demand for minimally invasive diagnostic" "procedures"

The primary driver of the Robotic Biopsy Devices Market Market is the increasing demand for accurate, minimally invasive biopsy procedures across oncology specialties. In 2023 about 44.1% of global robotic biopsy usage was for lung biopsy, illustrating strong need in thoracic diagnostics. Approximately 65% of tertiary hospitals now use robotic-assisted biopsy equipment in lung, prostate or brain applications. For B2B suppliers and OEMs, this driver means higher procurement volumes, longer lifecycle service contracts and investment in precision robotics tailored to oncology diagnostics.

RESTRAINT

"High capital expenditure, procedure reimbursement constraints and specialist training" "needs"

One of the major restraints in the Robotic Biopsy Devices Market Market is the high upfront cost of systems and limited reimbursement pathways. It is estimated that roughly 38% of potential hospital sites delay purchase due to cost and reimbursement uncertainty. Additionally, training and credentialing for interventional radiologists and surgeons represent about 22% of deployment overhead in many institutions. For B2B equipment manufacturers, this restraint means slower adoption in smaller clinics and increased need for flexible financing, rental models and service-based procurement frameworks within the Robotic Biopsy Devices Market Market.

OPPORTUNITY

"Expansion into outpatient centres, retrofit of existing systems and emerging-market" "growth"

The Robotic Biopsy Devices Market Market presents strong opportunities in service extension, networked outpatient deployment and emerging-market adoption. Outpatient and ambulatory surgical centres are projected to increase share of robotic biopsy procedures, recognising that less than 30% of current installations are in such centres. The instrument & accessories segment held about 55.9% revenue share in 2023, offering retrofit potential for older platforms. Asia-Pacific and Latin American regions have low penetration, with hospital adoption rates under 25% in many countries, signalling growth potential. For B2B suppliers, service-contract bundling, retrofit upgrade sales and localised manufacturing all represent strategic opportunities in the Robotic Biopsy Devices Market Market.

CHALLENGE

"Integration complexity across imaging systems, regulatory hurdles and market" "fragmentation by application"

A key challenge for the Robotic Biopsy Devices Market Market is the technical complexity of integrating robotic arms, imaging modalities (CT, MRI, ultrasound) and needle-tracking systems, which require multi-disciplinary collaboration and lengthy validation cycles. Approximately 62% of product enhancements result from partnerships across robotics and imaging sector, indicating high interdependence. Regulatory compliance varies by region, and around 18% of potential units are delayed due to certification issues. Application-specific variation (lung, brain, prostate) adds fragmentation—lung biopsy alone accounted for about 44% share, while brain and prostate make up the remainder, requiring differentiated strategies from OEMs.

Robotic Biopsy Devices Market Segmentation

The Robotic Biopsy Devices Market Market segmentation is structured by type (Brain Biopsy, Lung Biopsy, Prostate Biopsy) and by application (Hospitals, Ambulatory Surgical Centres, Academic & Research Institutes). In 2023, the lung biopsy segment accounted for about 44% of application volume, brain biopsy near 28% and prostate biopsy about 33%. The hospital end-use channel captured roughly 69% of revenue share in 2023, while outpatient centres and academic institutions share the rest. These segmentation insights guide B2B procurement, product development and service-model strategy in the Robotic Biopsy Devices Market Market.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Brain Biopsy: Brain biopsy in the Robotic Biopsy Devices Market Market is used for neurosurgical sampling of intracranial lesions and deep brain tissue. In 2023 this type constituted approximately 28% of global robotic biopsy applications, driven by the need for high precision and minimally invasive access. Tertiary neurosurgical centres adopted robotic arms in nearly 52% of brain biopsy workflows. For B2B OEMs and service providers, this segment demands advanced imaging integration, small-form-factor robots and high-accuracy needle guidance systems aligned with the Robotic Biopsy Devices Market Market.

Lung Biopsy: Lung biopsy remains the largest type in the Robotic Biopsy Devices Market Market, with about 44.1% share in 2023, largely due to increasing lung cancer incidence and need for peripheral nodule access. Automated robotic guidance systems achieved targeting accuracy improvements of up to 15% in clinical use. Large oncology centres equipped more than 65% of robots for thoracic interventions in 2023. For B2B suppliers, lung biopsy presents the highest-volume segment and emphasizes imaging-compatible robotic systems, endoscopic access modules and workflow automation in the Robotic Biopsy Devices Market Market.

Prostate Biopsy: Prostate biopsy accounted for approximately 33% of application volume in the Robotic Biopsy Devices Market Market in 2023, given growing prostate cancer screening and preference for robotic guidance. Robotic prostate biopsy platforms reduced procedure time by up to 20% and sampling error by nearly 12% in pilot studies. Over 45% of large urology centres in North America installed robots for prostate biopsy by end of 2023. For B2B equipment manufacturers, prostate biopsy represents a premium application type with distinct regulatory pathways and service requirements within the Robotic Biopsy Devices Market Market.

BY APPLICATION

Hospitals: Hospitals represent the major application channel in the Robotic Biopsy Devices Market Market, commanding about 69% of revenue share in 2023. These institutions invest in full robotic systems, multi-organ compatibility, and multi-year service contracts. Approximately 70% of large cancer-centre hospitals in the U.S. deployed robotic biopsy equipment by 2023. For B2B suppliers, hospitals remain the primary procurement target, with procurement cycles spanning 4 to 6 years and service income representing up to 26% of lifecycle revenue.

Ambulatory Surgical Centers: Ambulatory surgical centres (ASCs) are a growing channel in the Robotic Biopsy Devices Market Market, accounting for an estimated 16% of unit deployments in 2023. These centres favour compact robotic biopsy platforms, quicker turnaround, and lower-cost models. In 2023, about 22% of new installations were in ASCs versus 14% in 2021. For B2B providers, ASCs represent opportunity for lighter-weight systems, subscription models and shorter service-contract durations.

Academic & Research Institutes: Academic and research institutes form approximately 15% of the application base in the Robotic Biopsy Devices Market Market. These end-users often invest in pilot robotic biopsy systems for novel application studies, multi-specialty workflows and integration with imaging research. In 2023 roughly 12% of new units globally were purchased by academic-research centres for lung, brain or prostate biopsy development. For B2B equipment manufacturers, this segment offers high-innovation traction, early-adoption references and co-development partnerships.

Robotic Biopsy Devices Market Regional Outlook

The global Robotic Biopsy Devices Market Market shows clear regional dominance led by North America, accounting for about 57.8% of global share, supported by advanced hospital infrastructure and high adoption of precision robotic systems. Europe follows with nearly 28% share, driven by strong oncology research networks and regulatory standardisation. Asia-Pacific represents an emerging high-growth region with approximately 12% share, supported by rising cancer incidence and healthcare investments. The Middle East & Africa region, holding around 3% share, is gradually expanding through private hospital adoption and government-backed diagnostic modernization programs.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

The North America region dominates the Robotic Biopsy Devices Market Market, holding approximately 57.8% of global revenue share in 2023. Within North America, the United States accounts for roughly 87.4% of regional market volume in 2023. Tertiary care hospitals in the U.S. achieved over 70% installation rate of robotic biopsy platforms by late 2023. Lung biopsy remains the predominant application with about 44% share of units, followed by prostate (33%) and brain (28%). For B2B suppliers, North America offers mature regulatory frameworks, high reimbursement rates, established service infrastructure and strong demand for upgrades and instrument renewals. However, unit growth is moderating compared with emerging regions due to high baseline penetration.

EUROPE

Europe holds approximately 28% of the Robotic Biopsy Devices Market Market share. Major national markets such as Germany, France and the United Kingdom collectively contribute more than 60% of European volume. Adoption in European oncology centres reached about 58% of large hospitals by 2023. Lung biopsy systems captured around 40% of European application demand, while prostate and brain each held approximately 28–30%. For B2B equipment vendors, Europe presents a premium market where low-volume orders and high-spec systems dominate; regulatory harmonisation and service logistics are critical in the region.

ASIA-PACIFIC

Asia-Pacific accounted for about 12% of global share of the Robotic Biopsy Devices Market Market in 2023. Countries such as China and India are seeing growth in robotic biopsy adoption, but penetration remains under 25% in most large-hospital systems. In 2023 plant data showed that image-guided robotic biopsy installations in Asia-Pacific upgraded by approximately 22% year-on-year. Lung biopsy systems led regionally with about 48% application share, followed by prostate 30% and brain 22%. For B2B players in the Robotic Biopsy Devices Market Market, Asia-Pacific is a high-volume opportunity region, yet requires localisation of service, financing models and training programmes.

MIDDLE EAST & AFRICA

The Middle East & Africa region constitutes under 3% of global share in the Robotic Biopsy Devices Market Market as of 2023. Adoption remains limited, with less than 15% of tertiary hospitals equipped with robotic biopsy platforms. In Gulf Cooperation Council (GCC) countries, approximately 9% of new installations in 2023 were robotic biopsy systems. For B2B suppliers, the region offers early-adopter premium opportunities in private hospitals and specialist diagnostic centres, but complex regulatory environments and service infrastructure pose challenges.

List of Top Robotic Biopsy Devices Companies

• Medtech SA
• iSYS Medizintechnik GmbH
• Renishaw plc
• Biobot Surgical Pte Ltd
• Medtronic
• Medrobotics

Top companies by market share:

• Medtronic: holds approximately 24% of global market share in robotic biopsy systems.
• Renishaw plc: controls roughly 19% of global share in 2023.

Investment Analysis and Opportunities

The Robotic Biopsy Devices Market Market offers significant investment opportunities across equipment manufacturing, service contracts, instrumentation and software solutions. With 65% of tertiary care hospitals using robotic-assisted biopsies and the instrument & accessories segment capturing 55.9% of revenue in 2023, investment in consumable-and-service models is particularly attractive. Autonomous and AI-enabled systems accounted for about 18% of new launches, signalling the next innovation wave. Emerging markets such as Asia-Pacific (12% share in 2023) possess growth potential, especially when paired with financing models and local service networks. For B2B investors and strategic suppliers, priorities include aftermarket service platforms, retrofit upgrade kits, OEM-agnostic consumables and cloud-based analytics for biopsy workflows in the Robotic Biopsy Devices Market Market.

New Product Development

New product development in the Robotic Biopsy Devices Market Market is focused on robotics with AI-navigation, image-fusion modules and multi-organ compatibility. In 2023 around 18% of new product introductions featured autonomous needle-guidance functionalities. Robotic platforms now offer interchangeable modules for lung, prostate and brain biopsies, reducing capital investment across applications. Some devices reduced sampling error by over 12% in pilot trials and cut procedure time by up to 20% for prostate biopsy. For B2B equipment vendors, the trend toward multi-specialty platforms, consumable-service bundles and data-driven upgrade paths is accelerating product life-cycles and recurring-revenue models in the Robotic Biopsy Devices Market Market.

Five Recent Developments

• In 2024 a robotic biopsy system provider launched a lung biopsy module that improved targeting accuracy by 15% and captured over 9% of unit sales in oncology centres.
• In 2023 an instrument & accessories OEM entered partnership with an imaging-navigation vendor, representing around 62% of new product enhancements in the market.
• In 2025 a major manufacturer introduced a retrofit upgrade kit for existing biopsy systems, enabling instrument conversion to robotic guidance in 22% of deployed base.
• In late 2024 an outpatient imaging centre network in North America installed robotic biopsy systems in 16% of its sites, shifting 11% of biopsy volume from hospitals to ambulatory centres.
• In 2025 an Asia-Pacific healthcare chain announced rollout of robotic biopsy platforms across 47 hospitals, representing roughly 13% of region’s new installations for that year.

Report Coverage

This Robotic Biopsy Devices Market Market Research Report covers global market size (USD 424.3 million in 2023), segmentation by type (lung ~44.1%, brain ~28%, prostate ~33%) and by application (hospitals ~69% revenue share). Regional breakdowns include North America (~57.8% share), Europe (~28%), Asia-Pacific (~12%) and Middle East & Africa (~3%). The report also includes competitive landscape analysis (Medtronic ~24% share, Renishaw ~19% share), latest trends (autonomous systems ~18% of new launches), investment opportunities (instrument & accessories ~55.9% revenue share) and new product development data (accuracy improvement >12%, procedure time reduction ~20%). The Robotic Biopsy Devices Market Industry Report is designed for B2B stakeholders including OEMs, imaging-navigation suppliers, hospital procurement teams and service-contract providers seeking strategic insights, supply-chain optimisation and growth pathways in this evolving medical-device sector.

Robotic Biopsy Devices Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 433.41 Million in 2026
Market Size Value By	USD 1217.42 Million by 2035
Growth Rate	CAGR of 12.16% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Brain Biopsy Lung Biopsy Prostate biopsy By Application : Hospitals Ambulatory Surgical Centers Academic & Research Institutes
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample